8-K Announcements
6Material company update
Mar 11, 2026·SEC
Material company update
Feb 2, 2026·SEC
Material company update
Dec 18, 2025·SEC
Sagimet Biosciences Inc.(SGMT)Earnings, Financials & Key Ratios
SGMT•NASDAQ
$8.38
$271M mkt cap·Price updated May 6, 2026
AboutSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Show more
- Revenue$0
- EBITDA-$57M-24.8%
- Net Income-$51M-12.0%
- EPS (Diluted)-1.58-9.0%
- ROE-38.2%-3.5%
- ROIC-54.53%+35.9%
- Debt/Equity0.00+39.7%
SGMT Key Insights
Sagimet Biosciences Inc. (SGMT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SGMT Price & Volume
Sagimet Biosciences Inc. (SGMT) stock price & volume — 10-year historical chart
Loading chart...
SGMT Growth Metrics
Sagimet Biosciences Inc. (SGMT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.49%
Return on Capital
10 Years-62.32%
5 Years-50.09%
3 Years-46.15%
Last Year-42.58%
SGMT Recent Earnings
Sagimet Biosciences Inc. (SGMT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (82%)
Q2 2026Latest
Mar 11, 2026EPS
$0.29
Est $0.43
+32.6%
Revenue
—
Est $1M
Q4 2025
Nov 13, 2025EPS
$0.40
Est $0.41
+2.4%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.32
Est $0.52
+38.5%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.56
Est $0.79
+29.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 11, 2026 | $0.29vs $0.43+32.6% | —vs $1M |
| Q4 2025 | Nov 13, 2025 | $0.40vs $0.41+2.4% | — |
| Q3 2025 | Aug 13, 2025 | $0.32vs $0.52+38.5% | — |
| Q2 2025 | May 8, 2025 | $0.56vs $0.79+29.1% | — |
Based on last 12 quarters of dataView full earnings history →
SGMT Peer Comparison
Sagimet Biosciences Inc. (SGMT) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKBA | 392.83M | 1.48 | -74 | 47.46% | -2.26% | -16.39% | ||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 GNFT | 447.53M | 8.95 | 256.88 | 134.56% | -14.12% | -22.98% | 0.90 | |
 HIMS | 6.94B | 26.88 | 52.71 | 59% | 5.47% | 23.73% | 2.07 | |
 ALDX | 104.68M | 1.74 | -1.85 | -87.71% | 0.22 | |||
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 |
Compare SGMT vs Peers
Sagimet Biosciences Inc. (SGMT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGMT Income Statement
Sagimet Biosciences Inc. (SGMT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 2M | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | -100% | - |
| Cost of Goods Sold | 88K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -88K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 2M▲ 0% | 0▼ 100.0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | 100% | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | -100% | - |
| Operating Expenses | 14.07M | 11.4M | 23.72M | 31.05M | 32.74M | 54.45M | 56.89M |
| OpEx % of Revenue | - | - | - | - | 1637% | - | - |
| Selling, General & Admin | 5.68M | 3.22M | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| SG&A % of Revenue | - | - | - | - | 648.15% | - | - |
| Research & Development | 8.39M | 8.18M | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| R&D % of Revenue | - | - | - | - | 988.85% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.16M▲ 0% | -11.4M▲ 19.5% | -23.72M▼ 108.1% | -31.05M▼ 30.9% | -30.74M▲ 1.0% | -54.45M▼ 77.1% | -56.89M▼ 4.5% |
| Operating Margin % | - | - | - | - | -1537% | - | - |
| Operating Income Growth % | - | 19.49% | -108.06% | -30.93% | 1.01% | -77.14% | -4.47% |
| EBITDA | -14.07M | -11.4M | -23.72M | -31.05M | -30.74M | -45.57M | -56.89M |
| EBITDA Margin % | - | - | - | - | -1537% | - | - |
| EBITDA Growth % | - | 18.99% | -108.08% | -30.93% | 1.01% | -48.23% | -24.85% |
| D&A (Non-Cash Add-back) | 88K | 1K | 0 | 0 | 0 | 0 | 0 |
| EBIT | -14.2M | -11.4M | -23.72M | -31.05M | -30.74M | -45.57M | -56.89M |
| Net Interest Income | 64K | 30K | 26K | 553K | 2.86M | 0 | 0 |
| Interest Income | 128K | 30K | 26K | 553K | 2.86M | 0 | 0 |
| Interest Expense | 64K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -102K | 30K | -723K | 556K | 2.86M | 8.89M | 5.85M |
| Pretax Income | -14.26M▲ 0% | -11.37M▲ 20.3% | -24.44M▼ 115.0% | -30.5M▼ 24.8% | -27.88M▲ 8.6% | -45.57M▼ 63.5% | -51.04M▼ 12.0% |
| Pretax Margin % | - | - | - | - | -1393.8% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -14.26M▲ 0% | -11.37M▲ 20.3% | -24.44M▼ 115.0% | -30.5M▼ 24.8% | -27.88M▲ 8.6% | -45.57M▼ 63.5% | -51.04M▼ 12.0% |
| Net Margin % | - | - | - | - | -1393.8% | - | - |
| Net Income Growth % | - | 20.27% | -114.97% | -24.78% | 8.6% | -63.46% | -12.01% |
| Net Income (Continuing) | -14.26M | -11.37M | -24.44M | -30.5M | -27.88M | -45.57M | -51.04M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.64▲ 0% | -0.51▲ 20.3% | -1.10▼ 115.7% | -1.38▼ 25.5% | -1.53▼ 10.9% | -1.45▲ 5.2% | -1.58▼ 9.0% |
| EPS Growth % | - | 20.31% | -115.69% | -25.45% | -10.87% | 5.23% | -8.97% |
| EPS (Basic) | -0.64 | -0.51 | -1.10 | -1.38 | -1.53 | -1.45 | -1.58 |
| Diluted Shares Outstanding | 22.17M | 22.17M | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Basic Shares Outstanding | 22.17M | 22.17M | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
SGMT Balance Sheet
Sagimet Biosciences Inc. (SGMT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.81M | 68.74M | 58.66M | 32.79M | 96.65M | 152.77M | 116.4M |
| Cash & Short-Term Investments | 10.21M | 68.7M | 56.73M | 32.34M | 94.9M | 151.25M | 113.12M |
| Cash Only | 10.21M | 68.7M | 56.73M | 158K | 75.14M | 75.84M | 35.02M |
| Short-Term Investments | 0 | 0 | 0 | 32.19M | 19.76M | 75.41M | 78.1M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 58K | 36K | 1.51M | 34K | 397K | 463K | 3.28M |
| Total Non-Current Assets | 345K | 221K | 369K | 239K | 73K | 7.49M | 78K |
| Property, Plant & Equipment | 318K | 194K | 342K | 212K | 73K | 77K | 78K |
| Fixed Asset Turnover | - | - | - | - | 27.40x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 7.41M | 0 |
| Other Non-Current Assets | 27K | 27K | 27K | 27K | 0 | 0 | 0 |
| Total Assets | 11.16M▲ 0% | 68.96M▲ 517.9% | 59.03M▼ 14.4% | 33.03M▼ 44.0% | 96.72M▲ 192.8% | 160.26M▲ 65.7% | 116.48M▼ 27.3% |
| Asset Turnover | - | - | - | - | 0.02x | - | - |
| Asset Growth % | - | 517.91% | -14.4% | -44.05% | 192.81% | 65.7% | -27.32% |
| Total Current Liabilities | 2.08M | 1.91M | 2.44M | 5.28M | 5.65M | 4.45M | 5.1M |
| Accounts Payable | 1.2M | 513K | 761K | 1.13M | 186K | 1.43M | 1.31M |
| Days Payables Outstanding | 4.97K | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 78K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 243K | 185K | 57K | 556K | 5K | 3.71M |
| Current Ratio | 5.21x | 35.99x | 24.04x | 6.21x | 17.09x | 34.30x | 22.82x |
| Quick Ratio | 5.21x | 35.99x | 24.04x | 6.21x | 17.09x | 34.30x | 22.82x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 134.4M | 202.96M | 214.85M | 214.7M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 211K | 65K | 224K | 78K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 134.19M | 202.89M | 214.63M | 214.62M | 0 | 0 | 0 |
| Total Liabilities | 136.47M | 204.87M | 217.29M | 219.98M | 5.65M | 4.45M | 5.1M |
| Total Debt | 341K | 210K | 348K | 211K | 65K | 78K | 78K |
| Net Debt | -9.87M | -68.49M | -56.38M | 53K | -75.07M | -75.76M | -34.94M |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -221.23x | - | - | - | - | - | - |
| Total Equity | -125.31M▲ 0% | -135.91M▼ 8.5% | -158.26M▼ 16.4% | -186.95M▼ 18.1% | 91.06M▲ 148.7% | 155.81M▲ 71.1% | 111.38M▼ 28.5% |
| Equity Growth % | - | -8.45% | -16.44% | -18.13% | 148.71% | 71.09% | -28.51% |
| Book Value per Share | -5.65 | -6.13 | -7.14 | -8.43 | 5.01 | 4.97 | 3.44 |
| Total Shareholders' Equity | -125.31M | -135.91M | -158.26M | -186.95M | 91.06M | 155.81M | 111.38M |
| Common Stock | 1K | 1K | 1K | 1K | 2K | 3K | 3K |
| Retained Earnings | -155.56M | -166.93M | -191.37M | -221.87M | -249.74M | -295.31M | -346.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -84K | 30K | 230K | 120K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGMT Cash Flow Statement
Sagimet Biosciences Inc. (SGMT) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.55M | -10.42M | -21.71M | -24.49M | -23.77M | -42.44M | -45.65M |
| Operating CF Margin % | - | - | - | - | -1188.3% | - | - |
| Operating CF Growth % | - | 1.29% | -108.43% | -12.81% | 2.96% | -78.55% | -7.58% |
| Net Income | -14.26M | -11.37M | -24.44M | -30.5M | -27.88M | -45.57M | -51.04M |
| Depreciation & Amortization | 1K | 0 | 0 | 130K | 0 | 0 | 0 |
| Stock-Based Compensation | 2.99M | 775K | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 75K | 104K | 883K | -215K | 98K | -1.11M | -8K |
| Working Capital Changes | 645K | 75K | -55K | 4.21M | -978K | -1.05M | -1.05M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 120K | -907K | 929K |
| Cash from Investing | -27K | 20K | 0 | -32.01M | 12.58M | -61.68M | 4.56M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -27K | 20K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 18.48M | 68.89M | 9.74M | -73K | 86.17M | 104.82M | 275K |
| Debt Issued (Net) | -3.36M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 12K | 1000K | 1000K | 275K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.06M | -85K | -3.51M | -931K | 0 |
| Net Change in Cash | 7.91M▲ 0% | 58.49M▲ 639.8% | -11.97M▼ 120.5% | -56.57M▼ 372.6% | 74.98M▲ 232.5% | 701K▼ 99.1% | -40.82M▼ 5923.0% |
| Free Cash Flow | -10.55M▲ 0% | -10.42M▲ 1.3% | -21.71M▼ 108.4% | -24.49M▼ 12.8% | -23.77M▲ 3.0% | -42.44M▼ 78.6% | -45.65M▼ 7.6% |
| FCF Margin % | - | - | - | - | -1188.3% | - | - |
| FCF Growth % | - | 1.29% | -108.43% | -12.81% | 2.96% | -78.55% | -7.58% |
| FCF per Share | -0.48 | -0.47 | -0.98 | -1.10 | -1.31 | -1.35 | -1.41 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.92x | 0.89x | 0.80x | 0.85x | 0.93x | 0.89x |
| Interest Paid | 136K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGMT Key Ratios
Sagimet Biosciences Inc. (SGMT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | -30.61% | -36.92% | -38.2% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -85.05% | -54.53% |
| Gross Margin | - | - | - | - | 100% | - | - |
| Net Margin | - | - | - | - | -1393.8% | - | - |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -221.23x | - | - | - | - | - | - |
| FCF Conversion | 0.74x | 0.92x | 0.89x | 0.80x | 0.85x | 0.93x | 0.89x |
| Revenue Growth | - | - | - | - | - | -100% | - |
SGMT SEC Filings & Documents
Sagimet Biosciences Inc. (SGMT) SEC filings — annual & quarterly reports (10-K, 10-Q)
SGMT Frequently Asked Questions
Sagimet Biosciences Inc. (SGMT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sagimet Biosciences Inc. (SGMT) grew revenue by 0.0% over the past year. Growth has been modest.
Sagimet Biosciences Inc. (SGMT) reported a net loss of $51.0M for fiscal year 2025.
Dividend & Returns
Sagimet Biosciences Inc. (SGMT) has a return on equity (ROE) of -38.2%. Negative ROE indicates the company is unprofitable.
Sagimet Biosciences Inc. (SGMT) had negative free cash flow of $45.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More SGMT
Sagimet Biosciences Inc. (SGMT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates